Stocks and Investing Stocks and Investing
Fri, February 10, 2023

Keay Nakae Reiterated (ARWR) at Strong Buy and Held Target at $60 on, Feb 10th, 2023


Published on 2024-10-28 01:33:21 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, Feb 10th, 2023.

Keay has made no other calls on ARWR in the last 4 months.



There are 7 other peers that have a rating on ARWR. Out of the 7 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $31 on, Tuesday, November 29th, 2022
  • Andrew Galler of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Tuesday, November 29th, 2022


These are the ratings of the 5 analyists that currently disagree with Keay


  • Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, February 8th, 2023
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $52 on, Tuesday, February 7th, 2023
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023
  • Luca Issi of "RBC Capital" Maintained at Buy with Decreased Target to $77 on, Tuesday, February 7th, 2023
  • Maury Raycroft of "Jefferies" Maintained at Strong Buy with Decreased Target to $75 on, Tuesday, November 29th, 2022
Contributing Sources